Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

University of Alberta

$40,000.00

O-linked protein glycosylation in bacteria: a toolbox for glycoengineering

EF 2015-16

Résumé
Diseases caused by pathogenic bacteria continue to be one of highest causes of mortality worldwide. The development of antibiotic resistance by pathogens is occurring at alarming rates. Therefore, alternative strategies for protection of public health are urgently needed, and one of the strategies is vaccination. Since many pathogenic bacteria are covered by long sugars (named polysaccharides), immune responses directed to these sugars will prevent colonization and infection. However, purified polysaccharide vaccines produce a transient immune response. To generate long-term protection, bacterial polysaccharides must be covalently attached to an appropriate protein carrier. These molecules are named ""conjugate vaccines"". The efficacy of conjugating bacterial polysaccharides to proteins is best illustrated by the Haemophilus influenzae type b conjugate vaccine that has virtually eradicated disease in immunized children in most parts of the world. Presently, the production of conjugate vaccines requires intricate synthetic and expensive chemical methods. Novel technologies are needed to make possible the globalization of the use of conjugate vaccines for the prevention of bacterial infections. It has recently been established that certain bacteria are naturally able to attach polysaccharides to proteins, using an enzyme called OTase. We and others have shown that bacteria can tolerate the manipulation of their glycosylation systems. Therefore, they constitute perfect toolboxes for engineering novel sugar-containing structures that may be used as vaccines. We want to understand how OTases work to understand more about this important process that occurs in nature. A better understanding of what polysaccharides and proteins can be used and how do OTases work will provide us with more opportunities to produce cheaper and better vaccines that can be used in Canada and in other part of the world.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
327076-2011
Name nom
Feldman, Mario
Department département
Biological Sciences
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2011
Award amount
40000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5200
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Microbiology
Research subject fr
Microbiologie
Partie
5
Nb partie
5
Application title
O-linked protein glycosylation in bacteria: a toolbox for glycoengineering
Keyword
NSERC
Application summary
Diseases caused by pathogenic bacteria continue to be one of highest causes of mortality worldwide. The development of antibiotic resistance by pathogens is occurring at alarming rates. Therefore, alternative strategies for protection of public health are urgently needed, and one of the strategies is vaccination. Since many pathogenic bacteria are covered by long sugars (named polysaccharides), immune responses directed to these sugars will prevent colonization and infection. However, purified polysaccharide vaccines produce a transient immune response. To generate long-term protection, bacterial polysaccharides must be covalently attached to an appropriate protein carrier. These molecules are named ""conjugate vaccines"". The efficacy of conjugating bacterial polysaccharides to proteins is best illustrated by the Haemophilus influenzae type b conjugate vaccine that has virtually eradicated disease in immunized children in most parts of the world. Presently, the production of conjugate vaccines requires intricate synthetic and expensive chemical methods. Novel technologies are needed to make possible the globalization of the use of conjugate vaccines for the prevention of bacterial infections. It has recently been established that certain bacteria are naturally able to attach polysaccharides to proteins, using an enzyme called OTase. We and others have shown that bacteria can tolerate the manipulation of their glycosylation systems. Therefore, they constitute perfect toolboxes for engineering novel sugar-containing structures that may be used as vaccines. We want to understand how OTases work to understand more about this important process that occurs in nature. A better understanding of what polysaccharides and proteins can be used and how do OTases work will provide us with more opportunities to produce cheaper and better vaccines that can be used in Canada and in other part of the world.